The Lung HIV Microbiome Project (LHMP) - Catalog

Name

The Lung HIV Microbiome Project (LHMP)

Accession Number

HLB01951515a

Acronym

LHMP

Related studies

BSI Study IDs

LHMP

Is public use dataset

False

Keywords

Has Study Datasets

False

Has Specimens

True

Specimen ID Type

Coded

Study Website

https://biostatcenter.gwu.edu/?pkey=54

The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.

False

Clinical Trial URLs
N/A
Study type

Epidemiology Study

Collection Type

Open BioLINCC Study

Cohort type

Adult

Interventions

Study Open Date (Data)

None

Study Open Date (Specimens)

2015-10-12

Date materials available

2015-10-08

Last updated

None

Study period

October 2009 – November 2015

Study Contacts
NHLBI Division

DLD

Classification

Lung

HIV study classification

HIV

COVID study classification

non-COVID

Pre-Website # of Specimens Shipped

0

# of Returned Specimens

90

Primary Publication URLs
N/A
Conditions

HIV-1
Lung Diseases

Objectives

To characterize the microbiome of the lung and respiratory tract, and enhance understanding of the role of the lung microbiome in preserving health or causing disease and in the divergent effects observed in HIV-infected versus uninfected individuals.

Background

The respiratory tract is constantly exposed to the external environment and serves as the portal of entry for many microbes. The characteristics and mix of organisms populating the respiratory tract, coupled with the state of local respiratory defenses are key factors in determining whether a person remains healthy or develops acute, chronic, or latent infection. Inflammation in the airways and lungs and how it progresses or is resolved affects not only local immune mediators and primary gas exchange functions, but may also have consequences for the whole immune system and the progression of diseases in other organs.


HIV-infected individuals are at high risk of developing pneumonias caused by pathogenic and opportunistic microorganisms. These respiratory infections frequently cause morbidity, are often life threatening, and may increase the rate of replication of HIV, accelerating the course of the disease. HIV-infected individuals experience a decrease in lung function following pneumonias which are not observed in normal, HIV-uninfected populations. Furthermore, lung infections and microbial colonizations are suspected in the etiology of HIV-associated emphysema and pulmonary hypertension. An increasingly important issue is that lung infections may play a role in inducing the immune reconstitution syndrome seen in some HIV-infected patients following initiation of multi-drug antiretroviral regimens.


Therefore, knowledge of the lung microbiome in healthy and diseased states may lead to the identification of predictors of disease progression and therapeutic targets for translation into better preventive and treatment strategies. The LHMP was developed as a cooperative network responsible for carrying out both joint protocols and integrating independent protocols that benefit from increased sample size. This effort was meant to provide initial data to develop further hypotheses addressing differences between HIV-infected and HIV-uninfected individuals.

Subjects

Eligible subjects included HIV positive and HIV negative adults. Participant eligibility for the LHMP was confirmed by each center according to the parameters of their individual protocols, which may also define additional inclusion or exclusion criteria.

Design

The LHMP brought the distinct efforts of six clinical centers together under a single infrastructure, creating a network that combined the expertise accumulated across the range of involved disciplines in a focused and concentrated collaboration. Since multiple studies were involved in the project, the research design of each study will vary with the objective of that study. All data and samples were collected during a baseline assessment for LHMP.

Conclusions

Disease classification

Publications

Mat types

Bronchial Lavage
Oral Wash (Saline)
Peripheral Blood Mononuclear Cells
Plasma

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process

  • Material Types

    Last Modified: Oct. 26, 2018, 10:54 a.m.
  • General Freeze/Thaw Status
  • Visits (Vials)
    10/26/2018
     
      Plasma PBMC Bronchial Lavage Oral Wash Total
    1 Visit Per Subject 556 52 1199 242 2049
     

    Last Modified: Oct. 26, 2018, 10:54 a.m.
  • Visits (Subjects)
    10/26/2018
     
      Plasma
    Total number of subjects Average volume (ml) per subject
    1 Visit Per Subject 140 1.22
     
      Bronchial Lavage
    Total number of subjects Average volume (ml) per subject
    1 Visit Per Subject 182 14.17
     
      Oral Wash
    Total number of subjects Average volume (ml) per subject
    1 Visit Per Subject 142 1.78
     
      PBMC
    Total number of subjects Average vials per subject
    1 Visit Per Subject 26.00 2.00
     

    Last Modified: Oct. 26, 2018, 10:54 a.m.